Navigation Links
GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season
Date:8/11/2008

th an acute evolving neurologic disorder, but should be considered when the disease process has been stabilized.

In a clinical trial with FLUARIX, adverse events included pain and redness at the injection site, muscle aches and fatigue. In clinical trials with FLULAVAL, the most common adverse events were pain, redness, and/or swelling at the injection site and headache, fatigue, myalgia, fever and malaise. Most adverse events in clinical trials were mild and self-limited. (See adverse reactions section of the Prescribing Information for each product for other potential adverse events.)

Vaccination with FLUARIX or FLULAVAL may not protect 100 percent of susceptible individuals. If Guillain-Barre syndrome has occurred within six weeks of receipt of prior influenza vaccine, the decision to give FLUARIX or FLULAVAL should be based on careful consideration of the potential benefits and risks.

GlaxoSmithKline: A Leader in Flu

GlaxoSmithKline has an active research and development program targeted at both seasonal and pandemic flu and has recently invested more than $2 billion to expand capacity for manufacturing its flu vaccines FLUARIX and FLULAVAL and its antiviral flu medication Relenza(R) (zanamivir for inhalation). GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline at http://www.gsk.com.

GlaxoSmithKline: A Leader in Vaccines

GlaxoSmithKline, with U.S. operations in Philadelphia, PA, and Research Triangle Park, NC, is one of the world's leading research-based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. GSK Biologicals (GSK Bio), one of the world's leading vaccin
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. China Biologic Products Begins Annual Maintenance of its Production Facilities
2. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
3. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
4. China Biologic Products Begins Operation of its Newly Constructed Plasma Collection Station in Qi He County, Shandong Province
5. Medimetriks Pharmaceuticals, Inc. Begins Operations
6. CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Companys Common Stock and Trading in Post-split Shares Begins May 9, 2008
7. Nikon Instruments Begins Direct Sales and Technical Support in Southern California and Rocky Mountain Territories
8. Thomson Scientific Begins Expansion of Web of Science
9. Ohio Task Force Begins Mission of Creating a New 21st Century Industry
10. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
11. SPO Medical Begins Shipping PulseOx 6000(TM) and PulseOx 6100(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... ... of FireflySci Inc. (FFS) in early 2015, the company continues to shake up the cuvette ... in a lab coat and Large Marge have been posted on the company’s Facebook page ... is proud to be the only cuvette manufacturer is the world that has an online ...
(Date:8/27/2015)... 2015 The National Necrotizing Fasciitis Foundation ... saved by doctors at Vanderbilt University Hospital in ... Pharmaceuticals and Dr. John Crew , director of ... Medical Center in Daly City, CA. ... approach, pioneered by Dr. Crew, that had previously saved ...
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its ... iLab Solutions as number 1,361 in growth for the three years through 2014. Being ... 0.1% fastest-growing privately held organizations in the country. , “We are thrilled to ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
Breaking Biology Technology:Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3
... an explanation as to where and how North Sea oil ... be the first step on the way to developing improved ... from Danish oil fields. , A research group at the ... of Copenhagen has investigated drill cores collected from North Sea ...
... Apex Bioventures Acquisition Corporation (NYSE Amex: PEX ... notice from NYSE Amex LLC (the "Exchange") that the ... accepted by the Exchange and the Company has been ... compliance with the continued listing standards of the Exchange.As ...
... China, May 11 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ... CSKI ), a leading,fully integrated pharmaceutical company producing ... announced that it will conduct a,conference call at 10:00 ... to discuss its first quarter of fiscal year 2009 ...
Cached Biology Technology:New Danish research shows how oil gets stuck underground 2Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex 2China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results 2China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results 3
(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
(Date:7/31/2015)... , 31 de julio de 2015 La 10 ... se celebrará por medio de BGI del 22 al 25 de ... Este año, la conferencia celebra su décimo ... ha convertido en una de las reuniones anuales más influyentes ... de las reuniones más dinámicas, entusiastas y mejores a nivel ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... New Rochelle, NY, December 2, 2010 For ... addressed at the highest level of government. With the ... the U.S. Department of Health and Human Services has ... - and supporting breastfeeding is prominent among them. ...
... scientists at the University of Leicester have recorded stunning ... European Space Agency satellite instruments have been observing ... points in space. Leicester scientists have used ... images of a snow-bound UK from observations on November ...
... of Chicago Medical Center is designed to offer surgeons ... new molecular and mechanical solutions to three age-old problems: ... between blood vessels), improving tissue healing after surgery and ... The conference, "Solving the most challenging surgical ...
Cached Biology News:New public health goals tackle obstacles to breastfeeding success 2Snow from space: University of Leicester releases satellite images of snow-bound UK 2Conference goals include better surgery and better surgeons 2Conference goals include better surgery and better surgeons 3
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
TXNL2 Antibody...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Request Info...
Biology Products: